Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)
Key Insights
- Biocon's estimated fair value is ₹228 based on 2 Stage Free Cash Flow to Equity
- Biocon's ₹253 share price indicates it is trading at similar levels as its fair value estimate
- The ₹285 analyst price target for BIOCON is 25% more than our estimate of fair value
In this article we are going to estimate the intrinsic value of Biocon Limited (NSE:BIOCON) by taking the expected future cash flows and discounting them to their present value. We will take advantage of the Discounted Cash Flow (DCF) model for this purpose. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow.
We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.
Check out our latest analysis for Biocon
The Model
We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate:
10-year free cash flow (FCF) forecast
2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | |
Levered FCF (₹, Millions) | ₹14.4b | ₹13.7b | ₹18.6b | ₹27.2b | ₹32.2b | ₹37.0b | ₹41.7b | ₹46.2b | ₹50.6b | ₹55.0b |
Growth Rate Estimate Source | Analyst x5 | Analyst x8 | Analyst x3 | Analyst x1 | Est @ 18.48% | Est @ 14.97% | Est @ 12.52% | Est @ 10.81% | Est @ 9.60% | Est @ 8.76% |
Present Value (₹, Millions) Discounted @ 16% | ₹12.4k | ₹10.1k | ₹11.9k | ₹14.9k | ₹15.2k | ₹15.0k | ₹14.6k | ₹13.9k | ₹13.1k | ₹12.2k |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = ₹133b
We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (6.8%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 16%.
Terminal Value (TV)= FCF2033 × (1 + g) ÷ (r – g) = ₹55b× (1 + 6.8%) ÷ (16%– 6.8%) = ₹624b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= ₹624b÷ ( 1 + 16%)10= ₹139b
The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is ₹272b. In the final step we divide the equity value by the number of shares outstanding. Relative to the current share price of ₹253, the company appears around fair value at the time of writing. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.
Important Assumptions
We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Biocon as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 16%, which is based on a levered beta of 0.968. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Biocon
- Debt is well covered by earnings.
- Earnings declined over the past year.
- Dividend is low compared to the top 25% of dividend payers in the Biotechs market.
- Expensive based on P/E ratio and estimated fair value.
- Annual earnings are forecast to grow faster than the Indian market.
- Debt is not well covered by operating cash flow.
- Dividends are not covered by cash flow.
Next Steps:
Whilst important, the DCF calculation ideally won't be the sole piece of analysis you scrutinize for a company. The DCF model is not a perfect stock valuation tool. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. For Biocon, we've compiled three fundamental items you should explore:
- Risks: Take risks, for example - Biocon has 4 warning signs (and 1 which shouldn't be ignored) we think you should know about.
- Future Earnings: How does BIOCON's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
PS. Simply Wall St updates its DCF calculation for every Indian stock every day, so if you want to find the intrinsic value of any other stock just search here.
Valuation is complex, but we're here to simplify it.
Discover if Biocon might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:BIOCON
Biocon
Engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally.
Good value with proven track record.